Previous 10 | Next 10 |
Dova Pharmaceuticals (NASDAQ: DOVA ) +32% as FDA OKs Dova's Doptelet for low blood platelets in ITP patients. More news on: Dova Pharmaceuticals, Inc., Atossa Genetics Inc., Zogenix, Inc., Stocks on the move, Read more ...
The FDA approves Dova Pharmaceuticals' (NASDAQ: DOVA ) supplemental marketing application for DOPTELET (avatrombopag) to include treatment of thrombocytopenia (low blood platelets) in adult patients with chronic immune thrombocytopenia who have failed to sufficiently respond to previous th...
Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication Company to Host Conference Call at 9am EST DURHAM, N.C., June 27, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a ph...
-Approval Based on Positive Efficacy and Safety Data from Two Phase 3 Clinical Trials- -Company Intends to Partner for the European Commercialization of DOPTELET- DURHAM, N.C., June 25, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company foc...
DURHAM, N.C., June 24, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced the Company will present four abstracts with data from studies of avatrombopag in patients with chronic immune thrombocytopenia (ITP) at the 65th International Society on Thrombosis and...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
DURHAM, N.C., May 28, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 11:00 a....
LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare and BioTech space. Initiations are on the following: Acer Therapeutics Inc. (ACER...
DURHAM, N.C., May 20, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 2:00 p.m. ET in New York, NY. A li...
News, Short Squeeze, Breakout and More Instantly...
Dova Pharmaceuticals Inc. Company Name:
DOVA Stock Symbol:
NASDAQ Market:
Dova Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / October 30, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Jagged Peak Energy Inc ( JAG ) related to...
NEW YORK, NY / ACCESSWIRE / October 19, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Ra Pharmaceuticals, Inc . ( RARX ) related to i...
NEW YORK / ACCESSWIRE / October 17, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Ra Pharmaceuticals, Inc . (NASDAQ: RARX ) relate...